Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles

被引:2
|
作者
Yoon, Deok Yong [1 ]
Daniels, Michael J. [2 ]
Willcocks, Rebecca J. [3 ]
Triplett, William T. [3 ]
Morales, Juan Francisco [1 ]
Walter, Glenn A. [4 ]
Rooney, William D. [5 ]
Vandenborne, Krista [3 ]
Kim, Sarah [1 ]
机构
[1] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Dept Pharmaceut, Orlando, FL 32827 USA
[2] Univ Florida, Dept Stat, Gainesville, FL 32611 USA
[3] Univ Florida, Dept Phys Therapy, Gainesville, FL USA
[4] Univ Florida, Dept Physiol & Aging, Gainesville, FL USA
[5] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR USA
关键词
Rare diseases; Duchenne muscular dystrophy; Quantitative imaging biomarkers; Model-informed drug development; Clinical trial simulation; Drug development tools; Disease progression; Magnetic resonance imaging; Six-minute walk distance; HANDLING DATA; QUANTIFICATION; BOYS; GROWTH; LIMIT;
D O I
10.1007/s10928-024-09910-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed to provide quantitative information on the utilization of MRI transverse relaxation time constant (MRI-T2) of leg muscles in DMD clinical trials by developing multivariate disease progression models of Duchenne muscular dystrophy (DMD) using 6-min walk distance (6MWD) and MRI-T2. Clinical data were collected from the prospective and longitudinal ImagingNMD study. Disease progression models were developed by a nonlinear mixed-effect modeling approach. Univariate models of 6MWD and MRI-T2 of five muscles were developed separately. Age at assessment was the time metric. Multivariate models were developed by estimating the correlation of 6MWD and MRI-T2 model variables. Full model estimation approach for covariate analysis and five-fold cross validation were conducted. Simulations were performed to compare the models and predict the covariate effects on the trajectories of 6MWD and MRI-T2. Sigmoid Imax and Emax models best captured the profiles of 6MWD and MRI-T2 over age. Steroid use, baseline 6MWD, and baseline MRI-T2 were significant covariates. The median age at which 6MWD is half of its maximum decrease in the five models was similar, while the median age at which MRI-T2 is half of its maximum increase varied depending on the type of muscle. The models connecting 6MWD and MRI-T2 successfully quantified how individual characteristics alter disease trajectories. The models demonstrate a plausible correlation between 6MWD and MRI-T2, supporting the use of MRI-T2. The developed models will guide drug developers in using the MRI-T2 to most efficient use in DMD clinical trials.
引用
收藏
页码:671 / 683
页数:13
相关论文
共 7 条
  • [1] Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy
    Kempen, J. C. E.
    Harlaar, J.
    van der Kooi, A. J.
    de Groot, I. J. M.
    van den Bergen, J. C.
    Niks, E. H.
    Verschuuren, J. J. G. M.
    Brehm, M. A.
    NEUROMUSCULAR DISORDERS, 2014, 24 (03) : 216 - 221
  • [2] Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill, Katharina
    Ille, Lena
    Schroeder, Sebastian A.
    Blaschek, Astrid
    Mueller-Felber, Wolfgang
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2015, 19 (06) : 640 - 646
  • [3] Use of the six-minute walk test to characterize golden retriever muscular dystrophy
    Acosta, Austin R.
    Van Wie, Emiko
    Stoughton, William B.
    Bettis, Amanda K.
    Barnett, Heather H.
    LaBrie, Nicholas R.
    Balog-Alvarez, Cynthia J.
    Nghiem, Peter P.
    Cummings, Kevin J.
    Kornegay, Joe N.
    NEUROMUSCULAR DISORDERS, 2016, 26 (12) : 865 - 872
  • [4] Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy
    Goemans, Nathalie
    vanden Hauwe, Marleen
    Signorovitch, James
    Swallow, Elyse
    Song, Jinlin
    PLOS ONE, 2016, 11 (10):
  • [5] Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids
    Goemans, Nathalie
    van den Hauwe, Marleen
    Wilson, Rosamund
    van Impe, Annelies
    Klingels, Katrijn
    Buyse, Gunnar
    NEUROMUSCULAR DISORDERS, 2013, 23 (08) : 618 - 623
  • [6] Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
    Mercuri, Eugenio
    Signorovitch, James Edward
    Swallow, Elyse
    Song, Jinlin
    Ward, Susan J.
    Pane, M.
    Mazzone, E.
    Messina, Sonia
    Vita, G. L.
    Sormani, M. P.
    D'Amico, A.
    Berardinelli, A.
    Magri, F.
    Comi, G. P.
    Baranello, G.
    Mongini, T.
    Pini, A.
    Battini, R.
    Pegoraro, E.
    Bruno, C.
    Politano, L.
    Previtali, S.
    Binks, M. H.
    Campion, G.
    Charnas, L.
    Kaye, E.
    Kelly, M.
    Morris, C.
    Reha, A.
    NEUROMUSCULAR DISORDERS, 2016, 26 (09) : 576 - 583
  • [7] Latent process model of the 6-minute walk test in Duchenne muscular dystrophy A Bayesian approach to quantifying rare disease progression
    Lennie, Janelle L.
    Mondick, John T.
    Gastonguay, Marc R.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (01) : 91 - 104